These highlights do not include all the information needed to use WEGOVY Manufacturer Novo Nordisk Pharmaceutical Industries, LP | Novo Nordisk A/S - 25a-B Effective date 2026-06-18 Label type HUMAN PRESCRIPTION DRUG LABEL Version 19 Source monthly-update Hydrated at 2026-07-17 21:41:15 Label at a glance# Product WEGOVY Active ingredient SEMAGLUTIDE Label structure 37 sections Boxed warning In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures
Insufficient protein consumption impairs muscle protein synthesis and repair
So patients are resorting to compounded versions of the active ingredients found in Ozempic and Mounjaro, semaglutide and tirzepatide, respectively
The overall AE profilepredominantly gastrointestinal symptomswas comparable to that reported in previous randomized and observational studies
We stay ahead of market shifts anticipating changes, evaluating impact and uncovering opportunities to save money and improve outcomes because a formulary is more than just a list of covered drugs
While theyre fundamentally similar medications, they differ slightly in their mechanism of action: Wegovy (semaglutide) is a GLP-1 agonist Zepbound (tirzepatide) is a dual agonist: GLP-1 + a glucose-dependent insulinotropic polypeptide (GIP) Both semaglutide and tirzepatide affect the hypothalamus and the hedonic eating centers, the brains center of appetite and cravings